Allied Investment Advisors LLC Acquires 18 Shares of Eli Lilly and Company (NYSE:LLY)

Allied Investment Advisors LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 7.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 270 shares of the company’s stock after acquiring an additional 18 shares during the period. Allied Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $208,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of LLY. Atlas Legacy Advisors LLC bought a new position in shares of Eli Lilly and Company during the 4th quarter worth about $590,000. Bank of Jackson Hole Trust bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $1,867,000. Klingman & Associates LLC lifted its position in Eli Lilly and Company by 4.0% in the fourth quarter. Klingman & Associates LLC now owns 1,725 shares of the company’s stock worth $1,332,000 after purchasing an additional 66 shares during the period. Kentucky Retirement Systems Insurance Trust Fund boosted its stake in Eli Lilly and Company by 50.3% during the fourth quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 35,110 shares of the company’s stock worth $27,105,000 after buying an additional 11,754 shares in the last quarter. Finally, Proactive Wealth Strategies LLC raised its stake in shares of Eli Lilly and Company by 184.2% in the 4th quarter. Proactive Wealth Strategies LLC now owns 1,256 shares of the company’s stock valued at $969,000 after buying an additional 814 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $866.69 on Thursday. The firm has a market capitalization of $822.77 billion, a P/E ratio of 74.01, a price-to-earnings-growth ratio of 1.35 and a beta of 0.42. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The firm’s fifty day moving average price is $797.80 and its two-hundred day moving average price is $845.87. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 86.26%. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its board has authorized a share repurchase plan on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.69%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 51.24%.

Analysts Set New Price Targets

Several research firms recently commented on LLY. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Wells Fargo & Company lowered their target price on Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. Truist Financial lifted their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Citigroup lowered their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Finally, Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $997.50.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.